-Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin in Reduction of OsteoArthritis Knee Pain
Sep 29, 2020 - ENP Newswire
SAN DIEGO - Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento') released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.
Dr. David Leiman, MD, a board certified anesthesiologist, Clinical Assistant Professor of Surgery, University of Texa...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
